However, the comparison of IST efficacy between pediatric AA patients with myeloid neoplasm-associated gene expression and those without requires verification with additional data.One study of 279 AA patients with a median age of 39 years (14–85 years) revealed that somatic variants were not significantly associated with treatment response or long-term survival (20), and a significant correlation was noted between TET2 variant and a favorable response to IST treatment (21). The gene discussed is TET2; the disease is myeloid neoplasm.